



CORRES. AND MAIL  
**BOX AF**

# 16  
JRP  
2/9/88

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

FUSSI et al

Serial No. 816,838

Group: 125

Filed: January 7, 1986

Examiner: Waddell

OLIGO-HETEROPOLYSACCHARIDES HAVING  
A HEPARIN-LIKE ACTIVITY .....

\* \* \* \* \*

DECLARATION UNDER RULE 132

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir:

I Erik Holmer, do hereby declare and say as follows:

- (1) I am a citizen of Sweden and reside at Svartviksvägen 19;  
161 32 Bromma, Sweden.
- (2) I received the degree of Ph.D. from the Swedish University of  
Agricultural Sciences, Uppsala, in 1987.
- (3) I currently hold a position as Head of Antithrombosis Section,  
R and D Cardiovascular at KabiVitrum AB, Stockholm. I have held  
my position at KabiVitrum for 12 years.
- (4) I have been involved in biochemical research since 1975. Througout  
my research career I have kept myself fully up to date with the  
relevant literature, and I am conversant with the published and  
known techniques in my field.
- (5) I have read and understood the specification and claims of United  
States patent application Serial No. 816,838.
- (6) I am a co-author of the Thrombosis Research reference (Vol. 2, p.  
575-583 (1976)) cited in the Office Action of February 4, 1987 in  
U.S. patent application Serial No. 816,838.

- (7) I have determined the ratio of Anti-X<sub>a</sub> to APTT of an oligoheteropolysaccharide (Hepar Industries designation: RD 12286) comprising depolymerized heparin having a molecular weight of 4900 and other characteristics as defined in claim 13 of U.S. patent application Serial No. 816,838. The ratio obtained was 1.86.
- (8) As indicated in the Thrombosis Research reference referred to above, a 5000 molecular weight heparin fraction obtained by gel filtration had an Anti-X<sub>a</sub>/APTT ratio of approximately 20.
- (9) I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Further, declarant sayeth not.

Signed this 4th day of November, 1987

.....*B.D. Holman*.....